ELVN insider buying and SEC filings, explained
Enliven Therapeutics, Inc. · CIK 1672619
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$52.0M
Planned sales (10b5-1)
$24.3M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 19, 2026 | Planned (10b5-1) | Benjamin Hohl (CFO) sold 6,018 shares at about $38.48 ($232K), marked as a 10b5-1 plan trade. Holdings down 14% to 38,000 shares. | SEC filing Filed Oct 21, 2026, 5:53 PM ET |
| Oct 19, 2026 | Planned (10b5-1) | Helen Louise Collins (Chief Medical Officer) sold 5,000 shares at about $38.47 ($192K), marked as a 10b5-1 plan trade. Holdings down 17% to 25,000 shares. | SEC filing Filed Oct 21, 2026, 5:51 PM ET |
| Sep 17, 2026 | Planned (10b5-1) | Benjamin Hohl (CFO) sold 6,018 shares at about $50.35 ($303K), marked as a 10b5-1 plan trade. Holdings down 14% to 38,000 shares. | SEC filing Filed Sep 21, 2026 |
| Sep 17, 2026 | Planned (10b5-1) | Helen Louise Collins (Chief Medical Officer) sold 5,000 shares at about $50.35 ($252K), marked as a 10b5-1 plan trade. Holdings down 17% to 25,000 shares. | SEC filing Filed Sep 21, 2026 |
| Aug 17, 2026 | Planned (10b5-1) | Benjamin Hohl (CFO) sold 6,018 shares at about $58.58 ($353K), marked as a 10b5-1 plan trade. Holdings down 13% to 40,036 shares. | SEC filing Filed Aug 19, 2026 |
| Aug 17, 2026 | Planned (10b5-1) | Helen Louise Collins (Chief Medical Officer) sold 5,000 shares at about $58.59 ($293K), marked as a 10b5-1 plan trade. Holdings down 17% to 25,000 shares. | SEC filing Filed Aug 19, 2026 |
| Aug 4, 2026 | Planned (10b5-1) | Mika K Derynck (Director) sold 158,795 shares at about $60.21 ($9.6M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Aug 6, 2026 |
| Jul 17, 2026 | Planned (10b5-1) | Benjamin Hohl (CFO) sold 6,018 shares at about $52.64 ($317K), marked as a 10b5-1 plan trade. Holdings down 12% to 46,054 shares. | SEC filing Filed Jul 21, 2026 |
| Jul 17, 2026 | Planned (10b5-1) | Helen Louise Collins (Chief Medical Officer) sold 5,000 shares at about $52.67 ($263K), marked as a 10b5-1 plan trade. Holdings down 17% to 25,000 shares. | SEC filing Filed Jul 21, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Lori Anne Kunkel (Director) sold 10,000 shares at about $50.49 ($505K), marked as a 10b5-1 plan trade. Holdings down 19% to 41,884 shares. | SEC filing Filed Jul 8, 2026 |
| Jun 22, 2026 | Sale | ORBIMED ADVISORS LLC (10% owner) sold 860,123 shares indirectly at about $45.36 ($39.0M). Indirect holdings down 12% to 6,555,102 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 2 other reporting owners. | SEC filing Filed Jun 24, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Benjamin Hohl (CFO) sold 6,018 shares at about $43.80 ($264K), marked as a 10b5-1 plan trade. Holdings down 11% to 51,000 shares. | SEC filing Filed Jun 22, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Helen Louise Collins (Chief Medical Officer) sold 5,000 shares at about $43.80 ($219K), marked as a 10b5-1 plan trade. Holdings down 17% to 25,000 shares. | SEC filing Filed Jun 22, 2026 |
| Jun 15, 2026 | Sale | ORBIMED ADVISORS LLC (10% owner) sold 281,408 shares indirectly at $45.02 ($12.7M). Indirect holdings down 4% to 7,388,902 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 2 other reporting owners. | SEC filing Filed Jun 17, 2026 |
| Jun 5, 2026 | Planned (10b5-1) | Lori Anne Kunkel (Director) sold 10,000 shares at about $34.54 ($345K), marked as a 10b5-1 plan trade. Holdings down 16% to 51,884 shares. | SEC filing Filed Jun 9, 2026 |
| May 18, 2026 | Planned (10b5-1) | Helen Louise Collins (Chief Medical Officer) sold 5,000 shares at about $39.79 ($199K), marked as a 10b5-1 plan trade. Holdings down 17% to 25,000 shares. | SEC filing Filed May 20, 2026 |
| Apr 17, 2026 | Planned (10b5-1) | Helen Louise Collins (Chief Medical Officer) sold 5,000 shares at about $47.67 ($238K), marked as a 10b5-1 plan trade. Holdings down 17% to 25,000 shares. | SEC filing Filed Apr 21, 2026 |
| Mar 25, 2026 | Planned (10b5-1) | Helen Louise Collins (Chief Medical Officer) sold 40,000 shares at about $35.10 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 62% to 25,000 shares. | SEC filing Filed Mar 27, 2026 |
| Mar 17, 2026 | Planned (10b5-1) | Helen Louise Collins (Chief Medical Officer) sold 5,000 shares at about $27.76 ($139K), marked as a 10b5-1 plan trade. Holdings down 17% to 25,000 shares. | SEC filing Filed Mar 19, 2026 |
| Mar 9–10, 2026 | Planned (10b5-1) | Helen Louise Collins (Chief Medical Officer) sold 40,000 shares between Mar 9 and Mar 10 at about $30.06 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 62% to 25,000 shares. | SEC filing Filed Mar 11, 2026 |
| Mar 6, 2026 | Sale | Benjamin Hohl (CFO) sold 10,000 shares at about $29.58 ($296K). Holdings down 16% to 51,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 10, 2026 |
| Feb 17, 2026 | Planned (10b5-1) | Helen Louise Collins (Chief Medical Officer) sold 45,000 shares at about $26.17 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 64% to 25,000 shares. | SEC filing Filed Feb 19, 2026 |
| Feb 17, 2026 | Planned (10b5-1) | Richard A. Heyman (Director) sold 1,230 shares indirectly at about $26.18 ($32K), marked as a 10b5-1 plan trade. Indirect holdings down 5% to 22,647 shares. | SEC filing Filed Feb 19, 2026 |
| Feb 6, 2026 | Planned (10b5-1) | Joseph P Lyssikatos (Chief Scientific Officer) sold 5,000 shares indirectly at about $29.04 ($145K), marked as a 10b5-1 plan trade. Indirect holdings down 1% to 740,188 shares. | SEC filing Filed Feb 10, 2026 |
| Jan 20, 2026 | Planned (10b5-1) | Joseph P Lyssikatos (Chief Scientific Officer) sold 20,000 shares indirectly at about $26.75 ($535K), marked as a 10b5-1 plan trade. Indirect holdings down 3% to 745,188 shares. | SEC filing Filed Jan 22, 2026 |
| Jan 20, 2026 | Planned (10b5-1) | Richard A. Heyman (Director) sold 1,230 shares indirectly at about $26.75 ($33K), marked as a 10b5-1 plan trade. Indirect holdings down 5% to 23,877 shares. | SEC filing Filed Jan 22, 2026 |
| Jan 9, 2026 | Planned (10b5-1) | Anish Patel (President / COO) sold 48,300 shares indirectly at about $27.98 ($1.4M), marked as a 10b5-1 plan trade. Indirect holdings down 18% to 215,011 shares. | SEC filing Filed Jan 13, 2026 |
| Jan 8–9, 2026 | Planned (10b5-1) | Joseph P Lyssikatos (Chief Scientific Officer) sold 132,500 shares indirectly between Jan 8 and Jan 9 at about $26.23 ($3.5M), marked as a 10b5-1 plan trade. Indirect holdings down 15% to 765,188 shares. | SEC filing Filed Jan 12, 2026 |
| Jan 8–9, 2026 | Planned (10b5-1) | Richard A. Heyman (Director) sold 13,920 shares indirectly between Jan 8 and Jan 9 at about $25.02 ($348K), marked as a 10b5-1 plan trade. Indirect holdings down 36% to 25,107 shares. | SEC filing Filed Jan 12, 2026 |
| Dec 19, 2025 | Planned (10b5-1) | Joseph P Lyssikatos (Chief Scientific Officer) sold 5,000 shares indirectly at about $16.84 ($84K), marked as a 10b5-1 plan trade. Indirect holdings down 1% to 897,688 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Anish Patel (President / COO) sold 6,663 shares indirectly at about $21.02 ($140K), marked as a 10b5-1 plan trade. Indirect holdings down 2% to 263,311 shares. | SEC filing Filed Dec 10, 2025 |
| Nov 19, 2025 | Planned (10b5-1) | Joseph P Lyssikatos (Chief Scientific Officer) sold 12,500 shares indirectly at about $22.33 ($279K), marked as a 10b5-1 plan trade. Indirect holdings down 1% to 902,688 shares. | SEC filing Filed Nov 21, 2025 |
| Nov 17, 2025 | Planned (10b5-1) | Samuel Kintz (CEO and Director) sold 12,500 shares indirectly at about $21.82 ($273K), marked as a 10b5-1 plan trade. Indirect holdings down 1% to 890,392 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 7, 2025 | Planned (10b5-1) | Anish Patel (President / COO) sold 6,667 shares indirectly at about $17.40 ($116K), marked as a 10b5-1 plan trade. Indirect holdings down 2% to 269,974 shares. | SEC filing Filed Nov 12, 2025 |
34 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ELVN in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.